Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13372095 | 0.89 | PREP (0.37) | ALDH1A1MAPTPREPSMN1; SMN2FAP | |
| SCHEMBL13347237 | 0.82 | DPP4 (0.50) | ALDH1A1MAPTPREPSMN1; SMN2FAP | |
| SCHEMBL8214179 | 0.81 | PREP (0.39) | MAPTPREPSMN1; SMN2FAPPKM | |
| SCHEMBL8285598 | 0.80 | KMT2A (0.47) | ALDH1A1MAPT | |
| SCHEMBL13452746 | 0.79 | POLB (0.41) | ALDH1A1MAPTPREPFAPDPP4 | |
| SCHEMBL13452790 | 0.78 | ALDH1A1 (0.44) | ALDH1A1EPHX2 | |
| SCHEMBL13452587 | 0.77 | DPP4 (0.46) | PREPFAPDPP4DPP7DPP8 | |
| SCHEMBL8214993 | 0.70 | PREP (0.39) | PREPFAPDPP4AKR1C3DPP7 | |
| SCHEMBL8218638 | 0.69 | PREP (0.45) | ALDH1A1PREPFAPDPP4TSHR | |
| SCHEMBL13371993 | 0.69 | KMT2A (0.47) | ALDH1A1MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-03-15 | — | — | US | disclosed |
| WO-2005047297-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | ALDH1A1 1316/4885MAPT 4848/4885PREP 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.